Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.

Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M, Hoshino T.

PLoS One. 2013 Aug 5;8(8):e71356. doi: 10.1371/journal.pone.0071356. Print 2013.

2.

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.

Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.

Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.

PMID:
25107571
3.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH.

Lung Cancer. 2011 Nov;74(2):310-7. doi: 10.1016/j.lungcan.2011.03.016. Epub 2011 Apr 29.

PMID:
21529986
4.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.

PMID:
20504223
5.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.

Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH.

Lung Cancer. 2012 Aug;77(2):421-6. doi: 10.1016/j.lungcan.2012.04.005. Epub 2012 May 1.

PMID:
22555222
6.

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

Zhang Q, Sun T, Kang P, Qian K, Deng B, Zhou J, Wang R, Jiang B, Li K, Liu F, Wu S, Tan Q.

Cancer Chemother Pharmacol. 2016 Mar;77(3):583-93. doi: 10.1007/s00280-016-2969-y. Epub 2016 Feb 3.

PMID:
26842788
7.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
8.

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.

Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H.

Cancer Sci. 2007 Sep;98(9):1336-43. Epub 2007 Jul 19.

10.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
11.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
12.

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS.

Lung Cancer. 2009 Sep;65(3):377-82. doi: 10.1016/j.lungcan.2008.12.005. Epub 2009 Jan 16.

PMID:
19150580
13.

Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.

Cubukcu E, Fatih Olmez O, Saraydaroglu O, Akcali U, Kanat O, Kurt E, Evrensel T, Manavoglu O.

Clin Transl Oncol. 2011 Nov;13(11):826-30. doi: 10.1007/s12094-011-0741-7.

PMID:
22082649
14.

ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.

Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J.

J Thorac Oncol. 2012 Apr;7(4):663-71. doi: 10.1097/JTO.0b013e318244bdd4.

15.

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.

Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.

Cancer Chemother Pharmacol. 2012 May;69(5):1277-87. doi: 10.1007/s00280-012-1834-x.

PMID:
22302408
16.

Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.

Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, Kucharczyk T, Homa I, Kozioł P, Ciesielka M, Chudziak D, Milanowski J.

Oncol Rep. 2013 Nov;30(5):2385-98. doi: 10.3892/or.2013.2696. Epub 2013 Aug 26.

PMID:
23982437
17.

Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.

Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.

Eur J Cancer. 2012 Dec;48(18):3378-85. doi: 10.1016/j.ejca.2012.06.011. Epub 2012 Jul 12.

PMID:
22795264
18.

Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.

Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J.

Folia Histochem Cytobiol. 2012 Apr 24;50(1):80-6. doi: 10.2478/18700.

19.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.

Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.

Cancer Chemother Pharmacol. 2009 Aug;64(3):565-73. doi: 10.1007/s00280-008-0907-3. Epub 2009 Jan 3.

PMID:
19123003
20.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.

Lung Cancer. 2008 Jun;60(3):401-7. Epub 2007 Nov 26.

PMID:
18036700

Supplemental Content

Support Center